BridgeBio's acoramidis shows significantly improved outcomes vs. tafamidis in real-world ATTR-CM study

BridgeBio's acoramidis was associated with significantly improved clinical outcomes versus tafamidis in ATTR-CM in an independent, real-world study of U.S. electronic health records, per a GlobeNewswire release.

Detected & updated continuously · Source: Nebula